BioPharmSignal logoBioPharmSignal

Biotech News

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANI Pharmaceuticals (ANIP)ANI PharmaceuticalsCompany update

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).

Related news

ANIPANI Pharmaceuticals2026-11-05 11:50 EST

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-04-20 10:50 EST

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

AMRXAmneal Pharmaceuticals2026-06-05 12:00 EST

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

CHRSCoherus BioSciences, Inc.2026-01-05 14:30 EST

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

AMRXAmneal Pharmaceuticals2026-09-18 20:01 EST

Amneal Announces FDA Approval and Launch of Lanreotide Injection

View all latest news

ANI Pharmaceuticals

Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone...

Recent company news

ANIPANI Pharmaceuticals2026-11-05 11:51 EST

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

ANIPANI Pharmaceuticals2026-11-05 11:50 EST

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-11-05 06:33 EST

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-11-03 11:55 EST

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

ANIPANI Pharmaceuticals2026-10-23 10:55 EST

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

Stock data

Close
69.62 USD
Market cap
1.7B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States